Everest Organics Ltd manufactures APIs and Intermediates.Product Profile: a) APIs: Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia and Gout, Anti Thrombotic, Anti Fungal, Anti Viral, Anti Emetics, Anti Diabetic, Insomnia, Skeletal muscle relaxant, Overactive Bladder, Rhino-Conjunctivitis, etc.b) Intermediates: Febuxostat, Ilaprazole…
Everest Organics has announced that its thirty-third annual general meeting will be conducted virtually via video conferencing. Ahead of the meeting, the company has completed the dispatch of annual reports and meeting notices to eligible shareholders. To facilitate voting on corporate resolutions, a remote e-voting window has been scheduled, supported...
Notice of 33rd Annual General Meeting of the Company along with 33rd Annual Report for the FY 2025-26 is enclosed
Everest Organics Limited has publicly announced its financial results for the quarter ended June 30, 2026. The company disseminated these results through newspaper advertisements published in 'The South India Times' (English) and 'Telugu Prabha' (Regional). This update is crucial for shareholders and potential investors, as it provides the latest insights...
The company's Board has approved the appointment of Mr. Srikanth Reddy Kolli and Mr. Subroto Banerjee as new Independent Directors, each for a five-year term. This move strengthens governance by re-constituting crucial committees including Audit, Nomination & Remuneration, Stakeholders Relationship, and CSR. The Board also approved the annual report for...
